Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Kontinuierliche Glukosemesssysteme bei Menschen mit Typ-2-Diabetes ohne Insulintherapie: systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien
Diabetes Technology & Therapeutics · 2024-04 · 26 (4) · 252-262
DOI: 10.1089/dia.2023.0390 ↗Auf einen Blick
Sechs RCTs mit 407 Menschen mit Typ-2-Diabetes ohne Insulintherapie zeigen unter CGM bessere glykämische Werte als unter SMBG.
Fragestellung
Verbessert CGM im Vergleich zu SMBG die Glukosekontrolle bei Menschen mit Typ-2-Diabetes ohne Insulintherapie?
Methode
Systematische Übersicht und Metaanalyse von RCTs; Suche in PubMed, Cochrane und Embase; Vergleich CGM vs. SMBG.
Ergebnisse
6 RCTs mit 407 Teilnehmenden. HbA1c: WMD −0,31 % (95 %-KI −0,42 bis −0,21; I²=0 %); Glukose: WMD −11,16 mg/dL (95 %-KI −19,94 bis −2,39); Zeit im Zielbereich: WMD 8,63 % (95 %-KI 4,54–12,71).
Schlussfolgerung der Autor:innen
rt-CGM und is-CGM waren im Vergleich zu SMBG mit einer Verbesserung der glykämischen Kontrolle bei Menschen mit T2D ohne Insulintherapie verbunden.
Kernaussagen
- HbA1c unter CGM geringer als unter SMBG
- Zeit im Zielbereich und Zufriedenheit höher
- 6 RCTs mit 407 Teilnehmenden
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 28.03.2024. Verfasst von Rafael Oliva Morgado Ferreira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Santa Catarina, Department of Internal Medicine, Florianopolis, Brazil. Hauptthemen laut MEDLINE: Blood Glucose, Continuous Glucose Monitoring, Diabetes Mellitus, Type 2, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Continuous glucose monitoring (CGM) has shown favorable outcomes in patients with type 2 diabetes (T2D) who are on insulin therapy. However, the efficacy of CGM in managing glucose levels in noninsulin-treated people with T2D remains controversial.
Methods
PubMed, Cochrane, and Embase were searched for randomized controlled trials (RCTs) comparing CGM to self-monitoring of blood glucose (SMBG) in people with T2D not using insulin. We computed weighted mean differences (WMDs) and standard mean differences (SMD) for continuous outcomes, with 95% confidence intervals (CIs). Heterogeneity was assessed using I 2 statistics. Statistical analyses were performed using R version 4.2.3.
Results
We included six RCTs comprising 407 noninsulin-treated people with T2D of whom 228 were randomized to CGM. Diabetes duration ranged from 5.4 to 13.9 years. The mean age was 57.9 years and the mean body mass index was 30.8 kg/m 2 . Four trials used real-time CGM (rt-CGM) and two intermittent scanning CGM (is-CGM). Compared with SMBG, CGM significantly reduced the glycated hemoglobin level (WMD −0.31%; 95% CI −0.42 to −0.21; I 2 = 0%), glucose level (WMD −11.16 mg/dL; 95% CI −19.94 to −2.39; I 2 = 0%), time in hypoglycemia level 2 (WMD −0.28%; 95% CI −0.52 to −0.03; I 2 = 91%), glucose time >180 mg/dL (WMD −7.75%; 95% CI −12.04 to −3.45; I 2 = 0%), and the standard deviation of glucose variation (WMD −4.00 mg/dL; 95% CI −6.86 to −1.14; I 2 = 0%). CGM also increased time in range (WMD 8.63%; 95% CI 4.54–12.71; I 2 = 0%) and treatment satisfaction (SMD 0.79; 95% CI 0.54–1.05; I 2 = 0%).
Conclusion
In this meta-analysis, rt-CGM and is-CGM were associated with improvement in glycemic control in people with T2D not using insulin when compared to SMBG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal University of Santa Catarina, Department of Internal Medicine, Florianopolis, Brazil.
- Private Practice, Talita Trevisan Endocrinologia, Itajaí, Brazil.
- Department of Internal Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.
ORCID-Profile: Rafael Oliva Morgado Ferreira, Eric Pasqualotto, Matheus Pedrotti Chavez, Beatriz Friedrichsen Marques, Simone van de Sande-Lee
Zitieren
APA
Ferreira, R. O. M., Trevisan, T., Pasqualotto, E., Chavez, M. P., Marques, B. F., Lamounier, R. N., & van de Sande-Lee, S. (2024). Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Technology & Therapeutics, 26(4), 252-262. https://doi.org/10.1089/dia.2023.0390
Vancouver
Ferreira ROM, Trevisan T, Pasqualotto E, Chavez MP, Marques BF, Lamounier RN, et al. Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Technology & Therapeutics. 2024;26(4):252-262. doi:10.1089/dia.2023.0390
BibTeX
@article{Ferreira2024,
author = {Ferreira, Rafael Oliva Morgado and Trevisan, Talita and Pasqualotto, Eric and Chavez, Matheus Pedrotti and Marques, Beatriz Friedrichsen and Lamounier, Rodrigo Nunes and van de Sande-Lee, Simone},
title = {Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
journal = {Diabetes Technology & Therapeutics},
year = {2024},
volume = {26},
number = {4},
pages = {252--262},
doi = {10.1089/dia.2023.0390}
}
EUVIMED